# Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

> **NCT01952132** · PHASE2 · COMPLETED · sponsor: **Omeros Corporation** · enrollment: 40 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** OMS643762
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01952132
- **Lead sponsor:** Omeros Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01952132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01952132, "Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01952132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*